Managing Director, FasterCures, Milken Institute Health
Sung Hee Choe is the managing director on the FasterCures team at the Milken Institute. She oversees the programmatic portfolio and is responsible for day-to-day operations.
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Cell and gene therapies are a new category of medicines transforming how we treat and potentially cure disease. Both cell and gene therapies seek to modify genetic material to fight disease. Cell therapies involve cultivating or modifying cells outside the body before injecting them into a patient. Gene therapies use genetic material to manipulate the expression of a gene or alter the properties of an individual’s cells.
Today, seven cell and gene therapies are approved for marketing in the US and fewer than 10 are approved in Europe. Dozens of new cell and gene therapies are expected to become available in the US in the coming years. According to recent research, more than 1,000 cell and gene therapies are currently in development, with 50–75 therapies expected to be approved in the US by 2030.
In response to this growing pipeline and the hope these therapies offer, FasterCures convened roundtables and discussions to bring to light the unique regulatory and access considerations posed by cell and gene therapies. On November 3, 2021, FasterCures brought together its stakeholder community, along with Peter Marks, director of CBER at FDA, in a virtual roundtable. The goals of the roundtable included taking stock of the current status of cell and gene therapies given the disruptions caused by the COVID-19 pandemic, and identifying opportunities for collective engagement in 2022.
This report summarizes the key takeaways from the November 3 roundtable, and considers the developments that will take place in cell and gene therapies in 2022.
LOS ANGELES — For the 19th year, the Milken Institute Global Conference will bring together leaders who drive change. From May 1 through May 4, more than 3,500 people from 55 countries and 45 states will gather for discussion across 11...
Submitted electronically Joni Rutter, Ph.D. National Center for Advancing Translational Sciences National Institutes of Health 6701 Democracy Blvd Bethesda, MD 20892-4874 Dear Director Rutter, FasterCures, a center of the Milken Institute...
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
In this discussion paper on social and regional factors in well-being, Milken Institute Health Economist Ken Sagynbekov examines gender-based health disparities across U.S. regions. He assesses the role of social and economic influences on...
Lung cancer, one of the most preventable diseases, surpasses all other cancer deaths worldwide. Of the 8.8 million people who died from some form of cancer in 2015, 1.69 million of them, or about 20 percent, succumbed to lung cancer...
Employers seek to support their employees while normalizing a whole-person approach to substance use disorders (SUD). The response to addiction and the opioid crisis requires a whole-of-society approach, including employers of all sizes...
FasterCures has long been at the forefront of shaping the national focus on biomedical innovation, with a singular goal of saving lives by accelerating scientific advances for all patients. FasterCures has been instrumental in advocating...
Los Angeles – April 15, 2021 – The Milken Institute Global Conference, an annual convening of global leaders in government, finance, health, academia, and philanthropy, will take place this fall from October 17-20, 2021 at The Beverly...
Milken Institute Global Conference Scheduled for October 17-20, 2021
“What outcomes matter to patients?” This question is asked at nearly every meeting in biomedical R&D and health care. As FasterCures has documented over the years, there is a big change afoot to place patients in the center of medical...
This study calculates the prevalence and economic effects of diseases related to obesity and overweight in the United States. These costs are paid by individuals and their households, employers, government, and society. The prevalence of...
Diversity awareness is becoming an essential element of many policy efforts, from access to health care and financial inclusion to initiatives addressing systemic racism and inequities. Yet most of these discussions and initiatives overlook...
As a country, we face an urgent need to develop and implement public health and health-care strategies that recognize obesity as a chronic disease, address disparities in multifaceted care, focus on person-centered solutions, and eliminate...
27 January 2024 (London, UK)—With a shift towards preventative healthcare needed by both the National Health Service (NHS) and the new United Kingdom (UK) government, innovative financing solutions are critical to ensuring the...
Paul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence.
